Clinical Trials Logo

Respiratory Tract Infections clinical trials

View clinical trials related to Respiratory Tract Infections.

Filter by:

NCT ID: NCT04960878 Completed - Gut Microbiota Clinical Trials

The Effect of Synbiotics on the Upper Respiratory Tract Infection

Start date: October 5, 2020
Phase: N/A
Study type: Interventional

Gut microbiome manipulation to alter the gut-lung axis may potentially protect humans against respiratory infections. However, clinical trials of synbiotics, one of the microbiota-targeted intervention, in this regard is few. Therefore, this study aims to examine the effect of synbiotics on the incidence and severity of upper respiratory tract infection, gut microbiota composition and function, as well as biomarkers of immune function.

NCT ID: NCT04959955 Completed - COPD Exacerbation Clinical Trials

Project to Improve the Diagnosis and Treatment Ability of Adult Severe Community Acquired Lower Respiratory Tract Infection

Start date: August 8, 2015
Phase:
Study type: Observational

1. Objective to understand the proportion of atypical pathogens in the pathogens of SCAP and AECOPD in urban hospitals in China. 2. Objective to investigate the antimicrobial resistance of atypical pathogens in patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) and SCAP in urban hospitals. 3. Objective to master the important clinical characteristics of patients with acute exacerbation of SCAP and COPD caused by atypical pathogens and mixed infection in urban hospitals in China, and to put forward the experience judgment index. 4. Objective to evaluate the advantages of various diagnostic methods for atypical pathogens causing lower respiratory tract infection. 5. It is suggested that the current empirical treatment of SCAP and severe COPD in China should be improved.

NCT ID: NCT04959760 Completed - Clinical trials for COVID-19 Respiratory Infection

BinaxNow COVID-19 IgG Rapid Test Device and Antibody Self Test

Start date: June 3, 2021
Phase: N/A
Study type: Interventional

Performance evaluation of the BinaxNOW™ COVID-19 IgG Rapid Test Device (Professional Use) and with BinaxNOW™ COVID-19 Antibody Self Test wehn used with fingerstick capillary whole blood and plasma samples. The BinaxNOW™ Antibody Tests are lateral flow tests that measure SARS-CoV-2 IgG antibodies.

NCT ID: NCT04955821 Not yet recruiting - Clinical trials for VAP - Ventilator Associated Pneumonia

Early Identification of Pathogens in Children With Respiratory Tract Infection by Mechanical Ventilation Using mNGS

Start date: May 1, 2024
Phase:
Study type: Observational

VAP(Ventilator-associated pneumonia)is the most common complication of mechanical ventilation in severely ill patients. VAP is defined as pneumonia occurring 48 hours after patients receive mechanical ventilation, including pneumonia occurring within 48 hours after extubation. It is one of the important causes of hospital-acquired infection, and the incidence of VAP in children on mechanical ventilation is about 10%, or 7/1000 days of mechanical ventilation, and the overall mortality is 10-24%.Research has so far explained the relationship between bacteria isolated from human biological samples and VAP pathogens. Most studies are limited to the level of bacterial species, and there are few reports on bacterial genotyping, and there is a lack of scientific basis for the pathogenesis of VAP caused by bacteria in ventilator pipeline. The aim of the study is to investigate pathogen of the sputum in deep respiratory tract of patients with mechanical ventilation in PICU by the means of second generation sequencing (NGS).

NCT ID: NCT04955756 Recruiting - Clinical trials for Acute Respiratory Infection

Early Identification and Severity Prediction of Acute Respiratory Infectious Disease

ESAR
Start date: April 4, 2021
Phase: N/A
Study type: Interventional

Early identification and Severity prediction of Acute Respiratory infectious disease has become a top priority for clinicians at department of infectious and respiratory diseases after COVID-19 broke out. This is a multicenter, prospective, and randomized study, which aims to figure out the best way of early identification and severity prediction of acute respiratory infectious diseases. Patients with suspected acute respiratory infectious diseases will be enrolled into this study and received two different diagnostic pathways.

NCT ID: NCT04955327 Completed - Clinical trials for Upper Respiratory Tract Infection

To Compare the Efficacy and Tolerability of A. Paniculata/A. Chilensis in Individuals With URTI

A Paniculata
Start date: March 20, 2021
Phase: Phase 3
Study type: Interventional

Conventional therapy of upper respiratory tract infection (URTI) is not always effective and sometimes leads to side effects and also to inappropriate use of antibiotic. Hence, a search for safe and effective further treatment options is justified and would be a welcome addition to available conventional treatment. Use of plant based dietary supplements has become increasingly popular over the last few decades or so. Research based on some plants is more than centuries old and its main therapeutic objective is to stimulate the self-healing power of the body. Andrographolide was docked successfully in the binding site of SARS-CoV-2 Mpro. Computational approaches also predicts this molecule to have good solubility, pharmacodynamics property and target accuracy. This molecule also obeys Lipinski's rule, which makes it a promising compound to pursue further biochemical and cell based assays to explore its potential for use against COVID-19. A. Paniculata is a patented extract, standardized to Andrographolide, 14-deoxyandrographolide, and Neo-andrographolide. Maqui contains Maqui Berry Extract of Aristotelia Chilensis (10% Anthocyanidin, 8% Delphinidin) belonging to the family of Elaeocarpaceae, which has been known for its use in several conditions such as sore throat, fever and several other ailments. In the present study, the therapeutic potential of Andrographis Paniculata and Aristotelia chilensis as single ingredients as well as in combination will be evaluated in participants with common cold and COVID related symptoms. The products to be evaluated have been rigorously standardized and are available under the brand names of A. Paniculata and A. Chilensis. Literature indicates that both A. Paniculata and A.Chilensis are effective and safe in the treatment of typical cold-related symptoms in adults.

NCT ID: NCT04949386 Not yet recruiting - Long COVID Clinical Trials

Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.

Start date: September 2021
Phase: Phase 2
Study type: Interventional

This is a randomized (1:1) , placebo-controlled phase II study to evaluate the safety, tolerability and efficacy of S-1226 in Post-COVID-19 subjects (n≤48) with persistent respiratory symptoms. Subjects will receive twice daily treatments of either Placebo or S-1226 (8%) for 7 days.

NCT ID: NCT04949230 Completed - Covid19 Clinical Trials

A Retrospective Study of COVID-19 Treatments

Start date: February 19, 2021
Phase:
Study type: Observational

Surveys administered to subjects who have recovered from COVID-19 to assess how effective their treatment was.

NCT ID: NCT04949074 Completed - Clinical trials for Respiratory Tract Infections

Collection of RNA Extracted From Nasopharyngeal and Saliva Samples From Same Patients With Suspicion of Covid-19

COLL001
Start date: August 1, 2021
Phase:
Study type: Observational [Patient Registry]

Constitution of a collection of SARS-CoV-2 RNA extracts from nasopharyngeal and saliva / sputum samples, from the same patients (paired samples), taken during the same consultation in an indication of detection of SARS-CoV-2 in with a view to developing tests / diagnostic tools for SARS-CoV-2.

NCT ID: NCT04948515 Completed - Clinical trials for COVID-19 Respiratory Infection

Gene Polymorphism of IL17 and IL 23

COVID 19IL17
Start date: June 3, 2021
Phase:
Study type: Observational [Patient Registry]

rates are in such considerable amount among large population base. The pathogenesis of COVID-19 implicates a potent inflammatory response, involving a complex group of mediators including interleukins. These pleiotropic cytokines are secreted at the region of inflammation and released into the circulation by a variety of different cell types, including macrophages, lymphocytes, endothelial cells, epithelial cells during sepsis and acute organ injuries. There has recently found a number of studies reporting that the cytokine storms take part in the course of COVID-19